Twinbeech Capital LP Cassava Sciences Inc Transaction History

Twinbeech Capital LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$21.59 - $27.88 $1.24 Million - $1.6 Million	-57,423 Reduced 73.61%	20,588 $504,000
Q1 2023 May 15, 2023	BUY	$23.46 - $36.44 $1.41 Million - $2.19 Million	60,051 Added 334.36%	78,011 $1.88 Million
Q4 2022 Feb 14, 2023	BUY	$27.82 - $44.16 $499,647 - $793,113	17,960 New	17,960 $530,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $110M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.